-
公开(公告)号：US20120294868A1
公开(公告)日：2012-11-22
申请号：US13266082
申请日：2010-04-26
申请人： James R. Edwards , Gregory R. Mundy , Helen Mundy
发明人： James R. Edwards , Gregory R. Mundy , Helen Mundy
IPC分类号： A61K39/395 , A61P19/10 , A61P19/08 , A61P19/00
CPC分类号： C07K16/24 , A61K2039/505 , A61K2039/545 , C07K16/22 , C07K2317/76
摘要： The invention regards the modulation of TGF-β activity by administering to a subject an antibody that binds to TGF-β, thereby increasing bone growth, bone formation, bone mass and bone strength. The antibody acts to increase osteoblast number and function while at the same time decreasing osteoclast number and function. Such drugs are useful in the treatment of diseases or disorders such as osteoporosis, Paget's disease, metastatic bone cancer, myeloma bone disease, bone fractures, etc.
摘要翻译： 本发明涉及TGF- 通过向受试者施用结合TGF-β1b的抗体，从而增加骨生长，骨形成，骨量和骨强度的活性。 抗体的作用是增加成骨细胞数量和功能，同时减少破骨细胞数量和功能。 这些药物可用于治疗诸如骨质疏松症，佩吉特氏病，转移性骨癌，骨髓瘤骨病，骨折等疾病或病症。
-
公开(公告)号：US20110184057A1
公开(公告)日：2011-07-28
申请号：US13014170
申请日：2011-01-26
申请人： Gregory R. Mundy , Helen Mundy , Tadmor Shalon , Samuel P. Sawan
发明人： Gregory R. Mundy , Helen Mundy , Tadmor Shalon , Samuel P. Sawan
IPC分类号： A61K31/351 , A61K31/222 , A61P35/00 , A61P25/28
CPC分类号： A61K9/0019 , A61K31/35 , A61K45/06 , A61K2300/00
摘要： Cancer patients, patients with cognitive dysfunction, or patients with pulmonary hypertension are treated with parenterally administered therapeutic doses of statins. Particularly, transdermal, injection employing liquid infusion or particles are employed. For cancer, the statins may be used by themselves or in conjunction with a chemotherapeutic regimen. Liver cancer is treated orally with super doses of statins.
摘要翻译： 癌症患者，认知功能障碍患者或肺动脉高压患者用胃肠外给药的治疗剂量的他汀类药物治疗。 特别地，采用使用液体输注或颗粒的透皮，注射剂。 对于癌症，他汀可以自己使用或与化疗方案联合使用。 用超级剂量的他汀类药物口服治疗肝癌。
-
公开(公告)号：US06838436B1
公开(公告)日：2005-01-04
申请号：US09695807
申请日：2000-10-23
IPC分类号： A61K8/64 , A61K31/00 , A61K31/351 , A61K31/365 , A61K31/4015 , A61K31/522 , A61K38/05 , A61K38/06 , A61K38/07 , A61K45/06 , A61Q7/00 , A61K38/00
CPC分类号： A61K8/64 , A61K31/00 , A61K31/351 , A61K31/365 , A61K31/4015 , A61K31/522 , A61K31/7042 , A61K38/05 , A61K38/06 , A61K38/07 , A61K45/06 , A61Q7/00 , A61K2300/00
摘要： The present invention relates to compounds that inhibit the activity of the proteasome or the productions of proteasomal proteins and promote bone formation and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgey, and post-dental implantation, in subject where this is desirable.
摘要翻译： 本发明涉及抑制蛋白酶体活性或蛋白酶体蛋白的产生并促进骨形成的化合物，因此可用于治疗骨质疏松症，骨折或缺陷，原发性或继发性甲状旁腺功能亢进，牙周病或缺陷，转移性骨病， 溶骨性骨病，整形后手术，假体后关节活动和牙周后植入术，这是可取的。
-
公开(公告)号：US06656904B2
公开(公告)日：2003-12-02
申请号：US10050633
申请日：2002-01-15
IPC分类号： A01N3718
CPC分类号： A61K31/7042 , A61K8/64 , A61K31/00 , A61K31/351 , A61K31/365 , A61K31/4015 , A61K31/522 , A61K38/05 , A61K38/06 , A61K38/07 , A61K45/06 , A61Q7/00 , Y10S514/88 , A61K2300/00
摘要： The present invention relates to compounds that inhibit the activity of the proteasome or the production of proteasomal proteins and promote hair growth and the production of hair follicles and are thus useful in stimulating hair growth, including hair density, in subject where this is desirable.
摘要翻译： 本发明涉及抑制蛋白酶体活性或蛋白酶体蛋白的产生并促进毛发生长和毛囊生成的化合物，因此可用于在需要的受试者中刺激头发生长（包括毛发密度）。
-
公开(公告)号：US6017940A
公开(公告)日：2000-01-25
申请号：US806770
申请日：1997-02-26
IPC分类号： A61K31/196 , A61K31/4184 , A61K31/428 , A61K31/444 , A61K31/47 , A61K31/4709 , A61K31/498 , A61K31/517 , A61K31/53 , A61K31/655 , A61K31/425
CPC分类号： A61K31/655 , A61K31/196 , A61K31/4184 , A61K31/428 , A61K31/444 , A61K31/47 , A61K31/4709 , A61K31/498 , A61K31/517 , A61K31/53
摘要： Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or "linker" defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15 .ANG., are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.
-
公开(公告)号：US5614496A
公开(公告)日：1997-03-25
申请号：US458634
申请日：1995-06-02
IPC分类号： G01B21/20 , A61K38/00 , A61K38/18 , A61K38/22 , A61K45/00 , A61P1/02 , A61P5/00 , A61P19/08 , A61P19/10 , A61P43/00 , C07K14/50 , C12P21/02 , G01N21/35 , G01N21/85 , G01N33/10 , A61K38/16 , C07K14/475
CPC分类号： C07K14/501 , A61K38/1825 , C07K14/50 , G01N21/85 , G01N33/10 , Y10S530/84
摘要： The present invention provides therapeutic compositions for the prevention and treatment of pathological conditions involving bone and dental tissue. The present invention also provides a method to promote bone repair and/or growth for the treatment of pathological conditions involving bone tissue, for example, osteoporosis, Paget's disease, osteopetrosis, and periodontal disease and fracture repair, and healing of bone defects by administering FGF-1 to an animal or human in need of treatment.
摘要翻译： 本发明提供了用于预防和治疗涉及骨和牙齿组织的病理状况的治疗组合物。 本发明还提供一种促进骨修复和/或生长的方法，用于治疗涉及骨组织的病理状况，例如骨质疏松症，佩吉特氏病，骨硬化症，牙周病和骨折修复，以及通过施用FGF来治疗骨缺损 -1给需要治疗的动物或人类。
-
公开(公告)号：US5599708A
公开(公告)日：1997-02-04
申请号：US279675
申请日：1994-07-25
IPC分类号： A61K38/00 , C07K7/08 , C07K14/51 , C07K16/22 , C12N15/13 , A61K39/395 , C07K14/00 , C12P21/02
摘要： The present invention relates to a novel osteoclast growth regulatory factor, hereinafter referred to as "osteoclastpoietic factor (OPF)," which stimulates the formation of osteoclast bone cells, a process of preparing same, therapeutic and diagnostic uses thereof, antibodies to and antagonists of OPF, and assays for OPF, all of which relate to the development of therapeutics for the prevention and treatment of diseases involving bone tissue, for example, osteoporosis, Paget's disease and osteopetrosis.
摘要翻译： 本发明涉及一种新型破骨细胞生长调节因子，以下称为“破骨细胞生成因子（OPF）”，其刺激破骨细胞骨细胞的形成，其制备方法，其治疗和诊断用途，抗体和拮抗剂 OPF和OPF测定，所有这些都涉及用于预防和治疗涉及骨组织的疾病例如骨质疏松症，佩吉特氏病和骨硬化症的治疗剂的开发。
-
8.发明授权公开(公告)号：US06462019B1
公开(公告)日：2002-10-08
申请号：US09113947
申请日：1998-07-10
申请人： Gregory R. Mundy , I. Ross Garrett , G. Rossini
发明人： Gregory R. Mundy , I. Ross Garrett , G. Rossini
IPC分类号： A61K3800
CPC分类号： A61K45/06 , A61K8/64 , A61K31/00 , A61K31/165 , A61K31/166 , A61K31/27 , A61K31/351 , A61K31/366 , A61K31/40 , A61K31/4015 , A61K31/435 , A61K31/66 , A61K38/05 , A61K38/06 , A61K2800/91 , A61Q7/00 , G01N33/6872 , G01N2500/00 , Y10S514/88 , A61K2300/00
摘要： Compounds that inhibit the activity of NF-&kgr;B or inhibit the activity of the proteasome or both promote bone formation and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation.
摘要翻译： 抑制NF-κB活性或抑制蛋白酶体活性或两者促进骨形成的化合物有助于治疗骨质疏松症，骨折或缺陷，原发性或继发性甲状旁腺功能亢进，牙周病或缺损，转移性骨病，溶骨性骨 疾病，后整形手术，假体后关节手术和牙植入后。
-
公开(公告)号：US06342514B1
公开(公告)日：2002-01-29
申请号：US08808741
申请日：1997-02-28
申请人： Charles Petrie , Mark W. Orme , Nand Baindur , Kirk G. Robbins , Maria Kontoyianni , Gregory R. Mundy
发明人： Charles Petrie , Mark W. Orme , Nand Baindur , Kirk G. Robbins , Maria Kontoyianni , Gregory R. Mundy
IPC分类号： A61K31495
CPC分类号： A61K31/655 , A61K31/196 , A61K31/4184 , A61K31/428 , A61K31/444 , A61K31/47 , A61K31/4709 , A61K31/498 , A61K31/517 , A61K31/53
摘要： Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or “linker” defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15 Å, are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.
-
公开(公告)号：US6153631A
公开(公告)日：2000-11-28
申请号：US806768
申请日：1997-02-26
IPC分类号： A61K31/428 , A61K31/425
CPC分类号： A61K31/428
摘要： Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or "linker" defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15 .ANG., are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.
摘要翻译： 包含通过含有一个或多个原子的接头共价连接的两个芳族体系的化合物或定义为包含共价键本身的“连接体”，以使芳族体系在距离为1.5-15安培的范围内空间有效地处理与 骨缺损。 化合物可以单独施用于脊椎动物，或者与促进骨生长或抑制骨吸收的其它试剂组合施用。 可以通过评估其在影响与骨形态发生蛋白相关的启动子相关的报告基因的转录和/或刺激模型动物系统中颅骨生长的能力的能力来筛选其给药前的活性。
-
-
-
-
-
-
-
-
-
搜索结果
42 条记录 (耗时 0.032 秒)
